nach oben

Erschienen in:

01.03.2020 | News item

Possible risk of dysglycaemia with use of direct-acting antivirals

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

There is a link between use of direct-acting antivirals (DAAs) and the potential risk of abnormal blood sugar levels (dysglycaemia), according to a Health Canada review. …

Products included in Health Canada's review were: daclatasvir (Daklinza), sofosbuvir (Sovaldi), ledipasvir/sofosbuvir (Harvoni)sofosbuvir/velpatasvir (Epclusa), sofosbuvir/velpatasvir/voxilaprevir (Vosevi), elbasvir/grazoprevir (Zepatier), and glecaprevir/pibrentasvir (Maviret).

Health Canada. Summary Safety Review - Direct-acting antivirals (DAAs) - Health Canada. Internet Document : 17 Feb 2020. Available from: URL: https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&linkID=SSR00234

Titel: Possible risk of dysglycaemia with use of direct-acting antivirals
Publikationsdatum: 01.03.2020
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-020-75798-0

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Possible risk of dysglycaemia with use of direct-acting antivirals

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Gefitinib

Enoxaparin sodium overdose

Duloxetine

Chlormethine

Novartis launches external review on safety of brolucizumab

Prednisone